Table of Contents

List of Abbreviations ................................................................. XI

1. Introduction .............................................................................. 1
  1.1 Background of the study ....................................................... 1
  1.2 Statement of the problem ..................................................... 4
  1.3 Clinical significance of the study .......................................... 6
  1.4 Design and setting of the study ............................................ 7
  1.5 Objectives of the study ....................................................... 8

2. Materials and Methods .......................................................... 11
  2.1 Bone marrow preparation ................................................... 11
  2.2 BMSC isolation and cell culture ........................................... 11
  2.3 Passaging and in vitro differentiation of BMSC ....................... 12
  2.4 Comment on the characterization of in vitro cultivated BMSC ........................................................................... 14
  2.5 Fluorescent labeling of BMSC with PKH26 ......................... 14
  2.6 Animals and cell transplantation into the abdominal muscle .... 15
  2.7 Explantation of organs and preparation of tissue sections ....... 17
  2.8 Histological detection of transplanted cells ......................... 17
  2.9 Immunohistochemical analysis of tissue section ................... 17
  2.10 Explanation of antibody usage ........................................... 19
  2.11 Microscope and ApoTome™ analysis .................................. 21
  2.12 Labeling of motor end plates with alpha-bungarotoxin ...... 22
  2.13 Double-labeling and multicolor/ multi-channel documentation 23

3. Results ................................................................................... 25
  3.1 Cell cultures of native and to 5-AZA exposed human BMSC .... 25

  3.2 Histological detection of transplanted cells in cryosections .... 25
    3.2.1 Native BMSC in P1 with short time exposure (4d, 8d, 12d, 28d) .... 26
<table>
<thead>
<tr>
<th>4.3.2 Pretreatment methods - AZA and other ways of induction</th>
<th>94</th>
</tr>
</thead>
<tbody>
<tr>
<td>4.3.3 Differentiation in vivo and expression of markers</td>
<td>98</td>
</tr>
<tr>
<td>4.3.4 Functional Integration in vivo</td>
<td>106</td>
</tr>
</tbody>
</table>

**Part III. Clinical application and future prospects**

| 4.4 SUI: Definition, physiology and pathophysiology, epidemiology and conventional treatment | 109 |
| 4.5 Cell-based therapies as an option for the treatment of SUI | 112 |
| 4.6 Future Prospects | 115 |

5. **Abstract**

6. **References**

7. **Zusammenfassung**

8. **Appendix**

9. **Declaration**

10. **Acknowledgments**

11. **Conferences and Publications**

| 11.1 Conferences and Presentations | 147 |
| 11.2 Publications | 148 |

Eugen-Rehfisch-Award | 149 |